Chinese biopharmaceutical company Shanghai Junshi Biosciences Co. has filed for a US$414 million initial public offering in Hong Kong, according to a security filing released today.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!
Register NowAlready have an account or paid subscription? Log in
